NeuroOne reports successful large-animal StereoCED procedures; human studies planned this quarter

NEUROONE MEDICAL TECHNOLOGIES Corp

Three large-animal procedures completed using next-gen StereoCED platform at University of Minnesota.
In two procedures, drug delivery electrodes delivered study agent and recorded intracranial electrophysiological activity from same regions.
Robotic platform used for trajectory, drilling, and anchor bolt placement; drug delivery and recording successful.
StereoCED revenue expected in fiscal Q4 2026; human investigational device release planned by end of Q4 2026.
CEO Dave Rosa cites repeatability and progress toward human investigational clinical studies later this quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.